Stuart McIntosh

Experts / Stuart McIntosh

Clinical Reader in Surgical Oncology, Queen's University Belfast

Mr McIntosh is an active researcher in breast cancer, and is an Honorary Senior Lecturer within the Centre for Cancer Research and Cell Biology in Queen’s University Belfast. His interests are in: * the pre-surgical treatment of breast cancer, to try and reduce the amount of surgery necessary for women with a diagnosis of breast cancer * the use of drugs to reduce the risk of developing breast cancer in women with a high genetic risk * decision making and the provision of information for women making decisions about breast reconstruction following a mastectomy for breast cancer * the outcomes of breast reconstruction surgery, and the use of novel technology such as three dimensional photography to assess the outcomes of surgery He has published research papers in medical journals on these topics, and in 2014 was granted the degree of Doctor of Philosophy (PhD) from the University of Ulster for research in the field of surgical techniques in breast cancer. As Deputy Clinical Director of the Northern Ireland Cancer Trials Network, Mr McIntosh supports many research studies running across the United Kingdom and globally. He is a member of the National Cancer Research Institute Breast Clinical Studies Group, which is the body responsible for developing and promoting clinical trials in breast cancer to ensure that patients have access to the best possible standard of evidence-based treatment.

Billions is spent on cancer research globally – but is it money well spent?

In 2020, 19 million people around the world received a cancer diagnosis. By 2040, that number is expected to reach 28 million. Poorer countries will be especially hard hit, with an increasing number of cases and more deaths, compared with richer countries.

Billions is spent on cancer research globally – but is it money well spent?

In 2020, 19 million people around the world received a cancer diagnosis. By 2040, that number is expected to reach 28 million. Poorer countries will be especially hard hit, with an increasing number of cases and more deaths, compared with richer countries.

By Dr Michael Head, Prof Ramsey Cutress, Stuart McIntosh

Stuart McIntosh

Clinical Reader in Surgical Oncology, Queen's University Belfast

More from this expert

Billions is spent on cancer research globally – but is it money well spent?

In 2020, 19 million people around the world received a cancer diagnosis. By 2040, that number is expected to reach 28 million. Poorer countries will be especially hard hit, with an increasing number of cases and more deaths, compared with richer countries.

Billions is spent on cancer research globally – but is it money well spent?

In 2020, 19 million people around the world received a cancer diagnosis. By 2040, that number is expected to reach 28 million. Poorer countries will be especially hard hit, with an increasing number of cases and more deaths, compared with richer countries.

Get the app

Site

Company

Connect

Legal

Discover

Healthed

Stuart McIntosh

Clinical Reader in Surgical Oncology, Queen's University Belfast

More from this expert

Billions is spent on cancer research globally – but is it money well spent?

In 2020, 19 million people around the world received a cancer diagnosis. By 2040, that number is expected to reach 28 million. Poorer countries will be especially hard hit, with an increasing number of cases and more deaths, compared with richer countries.

Billions is spent on cancer research globally – but is it money well spent?

In 2020, 19 million people around the world received a cancer diagnosis. By 2040, that number is expected to reach 28 million. Poorer countries will be especially hard hit, with an increasing number of cases and more deaths, compared with richer countries.

Get the app

Site

Company

Connect

Legal

LOG IN FOR FULL ACCESS

SIGN UP FOR A FREE HEALTHED ACCOUNT

Extra Details

PASSWORD RESET

Discover

Healthed